Join our daily newsletter At The Bell to receive exclusive market insights
- Epsilon Healthcare (EPN) appoints Peter Giannopoulos as its newest CEO
- Mr Giannopoulos has more than 25 years of experience across the Australian healthcare system, having previously held the role of CEO at both Cell Therapies and Ramsay Healthcare (RHC)
- The new appointment comes with a $495,000 annual salary, inclusive of superannuation, plus short and long-term incentives
- The appointment becomes effective from Tuesday, May 23
- Epsilon Healthcare is up 16.7 per cent and trading at 2.1 cents at 12:09 pm AEST
Epsilon Healthcare (EPN) shares were up after appointing Peter Giannopoulos as its newest Chief Executive Officer.
The appointment follows an “extensive” search process by the board.
Mr Giannopoulos has more than 25 years of experience across the Australian healthcare system. He most recently led the Cell Therapies team as CEO, where he undertook capital-raising activities to grow revenue for its cell and gene therapy landscape.
Prior to Cell Therapies, he led the diversification of Australia’s largest private hospital provider, Ramsay Healthcare (RHC) over a 12-year period.
Under Mr Giannopoulos’s leadership, the company expanded Ramsay Pharmacy Group from a single site in 2007 to a 90-site operation, generating revenues of more than $400 million.
The new appointment comes with a $495,000 annual salary inclusive of superannuation, plus short and long-term incentives.
The appointment will become effective from Tuesday, May 23.
EPN was up 16.7 per cent and trading at 2.1 cents at 12:09 pm AEST.
